MediWound (MDWD) Misses Q3 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
Go back to MediWound (MDWD) Misses Q3 EPS by 35c
October 27, 2015 4:30 PM EDT
YAVNE, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months ended September 30, 2015.
Highlights of the third quarter of 2015 and recent weeks include:
Awarded contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $112 million for the development and procurement of NexoBrid for the U.S.
Completed enrollment in second Phase 2 clinical trial with...
More
October 27, 2015 4:30 PM EDT
YAVNE, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months ended September 30, 2015.
Highlights of the third quarter of 2015 and recent weeks include:
Awarded contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $112 million for the development and procurement of NexoBrid for the U.S.
Completed enrollment in second Phase 2 clinical trial with...
More
